Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Stock Information for Prelude Therapeutics Incorporated

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Prelude Therapeutics Incorporated

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Context Therapeutics to Participate in Upcoming Investor Conferences
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.